Dr Quentin Anstee
Clinical Senior Lecturer & Consultant Hepatologist

  • Email: quentin.anstee@ncl.ac.uk
  • Telephone: +44 (0) 191 208 7012
  • Address: Institute of Cellular Medicine
    4th Floor, William Leech Building
    The Medical School
    Framlington Place
    Newcastle University
    Newcastle-Upon-Tyne, NE2 4HH

Introduction

Dr Quentin M. Anstee is an Academic Hepatologist in the Institute of Cellular Medicine. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Unit at the Freeman Hospital, Newcastle.

Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and management of Non-Alcoholic Fatty Liver Disease & Steatohepatitis (NAFLD/NASH), including the identification of genetic and epigenetic modifiers of Hepatic Fibrosis progression. He co-ordinates the European Union Horizon 2020 funded EPoS: Elucidating Pathways of Steatohepatitis consortium (EPoS) and is actively involved in biomarker discovery projects and ongoing clinical trials of new therapies for NAFLD.

Clinical Expertise

Dr Anstee's clinical practice is based in the Regional Liver Unit at the Freeman Hospital. His particular specialist interest is the diagnosis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), an increasingly common, progressive liver disease that is strongly associated with features of the 'metabolic syndrome' (including obesity, type 2 diabetes mellitus and dyslipidaemia). Working closely with Professor Chris Day, he leads the regional NAFLD specialist clinical service based at the Freeman Hospital, Newcastle.

Dr Anstee trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997).

His post-graduate specialist clinical training in Hepatology/Gastroenterology & General Medicine was undertaken at hospitals in North-West London. Prior to joining ICM, he worked as Clinical Lecturer in Medicine & Hepatology at Imperial College London and St Mary's Hospital from 2007-2010.

He has expertise in the management of patients with a range of acute and chronic liver conditions including:

  • Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis (NASH)
  • Alcoholic Liver Disease
  • Chronic Viral Hepatitis (hepatitis B & hepatitis C)
  • Autoimmune hepatitis, PSC & PBC
  • Cirrhosis and Portal hypertension
  • Liver Transplantation

Qualifications

  • BSc(Hons) - 1st Class 'Cell Pathology & Basic Medical Sciences', UCL (1994)
  • MB BS with Distinction in Medicine, UCL (1997)
  • MRCP(UK), Royal College of Physicians (London, 2000)
  • PhD, Imperial College London (2007)
  • FRCP, Fellow of the Royal College of Physicians (London, 2016)

Memberships of Learned Societies

  • Association of Physicians of Great Britain and Ireland
  • British Association for the Study of the Liver (BASL)
  • European Association for the Study of the Liver (EASL)
  • American Association for the Study of the Liver (AASLD)

Esteem Indicators

Membership of Editorial Boards:

  • Journal of Hepatology
  • European Medical Journal - Hepatology

Peer Review Activity:

  • International journals including 'Nature Genetics', 'Nature Communications', 'Gastroenterology', 'Hepatology', 'Journal of Hepatology', 'Gut', 'Liver International', 'Journal of Viral Hepatitis', 'Mammalian Genome' & 'International Journal of Experimental Pathology'
  • Grant awarding bodies including the MRC, Wellcome Trust and NIHR.

Selected Invited Lectures at Recent National & International Meetings:

  • 'Making the Best Use of CRISPR-Cas9 Technology' Co-chair of Early Morning Workshop, 51st International Liver Congress, European Association for the Study of the Liver, 2016, Barcelona, Spain.
  • 'Genetics of NAFLD' International Symposium, CHOZEN Project, Kanazawa University, Japan, 2016.
  • 'Steatosis and Metabolic Risk Factors: who is at risk of liver disease progression?' 11th Barcelona International Meeting on Therapy in Liver Disease, Spain, 2015.
  • 'Genetics, Mechanisms & Management of NAFLD and ALD' Advanced Medicine 2015, Royal College of Physicians, London, 2015.
  • 'NASH - Diagnosis & Current Management' Co-chair of Early Morning Workshop, 49th International Liver Congress, European Association for the Study of the Liver, 2014, London, UK.
  • 'Genetics of NAFLD & ALD' Falk Forum on Autoimmune & Congenital Liver Disorders, 2014, London, UK. 
  • 'Genetics of NAFLD' & 'New Therapies for NAFLD' NAFLD: Basics to Clinical Practice - An INASL Initiative, 2014, Chandigarh, India. 
  • 'NAFLD: Clinical Research Update' British Society of Gastroenterology, 2013, Glasgow, UK.
  • 'SNPs, GWAS & NGS - Making Sense of the Alphabet Soup of Genomics' APASL, 2013, Singapore.
  • 'Targeting Patients at Risk of Progressive Non-Alcoholic Fatty Liver Disease - Whom and How?' 47th International Liver Congress, European Association for the Study of the Liver, 2012, Barcelona, Spain.
  • 'Experimental Models of NAFLD'  47th International Liver Congress, European Association for the Study of the Liver, 2012, Barcelona, Spain.
  • 'Targeted Therapy for Non-Alcoholic Fatty Liver Disease & The Metabolic Syndrome' Frontiers in Hepatology 2011, The Institute of Hepatology, London, UK.
  • 'Anticoagulants as Antifibrotics – Current Evidence in Man & Future Trials' 4th International Conference on Coagulopathy in Liver Disease, 2011, London, UK.
  • 'NASH - Pathogenesis & Management' Co-chair of Early Morning Workshop, 46th International Liver Congress, European Association for the Study of the Liver, 2011, Berlin, Germany.
  • 'The Role of Hypercoagulability in the Pathogenesis of Liver Fibrosis' 46th International Liver Congress, European Association for the Study of the Liver, 2011, Berlin, Germany.


Research Interests

Dr Anstee's primary research interest is the study of genetic modifiers of progressive liver disease. His translational research has extended from the bench to the bedside with particular focus on the pathogenesis and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD/NASH), gentic and epigenetic modifiers of Hepatic Fibrosis progression and identification of genetic factors that promote Alcohol Addiction. He co-ordinates the €6 million European Union Horizon 2020 funded EPoS: Elucidating Pathways of Steatohepatitis consortium (EPoS) and was a member of the preceeding European Union FP7 funded Fatty Liver: Inhibition of Progression (FLIP) consortium. Through these and other projects he has established ongoing fruitful collaborations with scientific partners based at several UK and international liver units.

Dr Anstee's scientific research has employed gene-driven and phenotype‐driven ethyl-nitrosourea (ENU) mutagenesis screens and more traditional targeted genetic modification techniques to generate and study models of complex genetic disease traits including alcohol addiction, non-alcoholic steatohepatitis, drug induced liver injury (paracetamol toxicity and antibiotic related idiosyncratic drug reactions) and liver fibrosis. He has a long-standing research collaboration with investigators at the MRC Mammalian Genetics Unit, MRC Harwell and leads the Genetics of Liver Disease (UK-GoLD) network.

He is a principal investigator in ongoing clinical trials of new therapies for fatty liver disease and hepatic fibrosis.


Funding

Dr Anstee has previously received a HEFCE Clinical Senior Lecturer Award and an MRC Clinical Research Fellowship to study genetic modifiers of Non-Alcoholic Steatohepatitis (NASH) & Liver Fibrosis.

He has received research grant funding from sources including the European Union, MRC, Wellcome Trust, Academy of Medical Sciences and the NIHR.

Projects

Undergraduate Teaching

  • Medicine & Surgery MB BS Course (CSIM3): Lecturer
  • Medicine & Surgery MB BS Course (NME2): Seminar Tutor
  • Biomedical Sciences BSc Course (BMS3020 - Chronic Disease): Lecturer
  • Biomedical Sciences BSc Course (BGM3061 - Integrated Genetics): Lecturer
  • MB BS Undergraduate Tutor

Lecture topics include: 'Non-Alcoholic Fatty Liver Disease (NAFLD)', 'Alcoholic Liver Disease', 'Viral Hepatitis (hepatitis C)', 'Cirrhosis & its Complications', 'Genetics of NAFLD'.

Postgraduate Teaching 

  • Medical Sciences MRes: Senior Tutor for Intercalating Students
  • MRes (Diabetes): Lecturer
  • MClinRes (MCR8006: Designing a Research Proposal): Lecturer
  • MClinRes (MCR8004: Developing Your Career in Clinical Research): Lecturer